

Svenja Nägling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5776694/publications.pdf>

Version: 2024-02-01

36
papers

1,147
citations

331670

21
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

1437
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	20.1	127
2	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	3.7	120
3	The Role of the Octarepeat Region in Neuroprotective Function of the Cellular Prion Protein. <i>Brain Pathology</i> , 2007, 17, 174-183.	4.1	109
4	Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies. <i>Endocrine Pathology</i> , 2012, 23, 21-33.	9.0	57
5	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 404-415.	11.4	56
6	Combined blockade of signalling pathways shows marked anti-tumour potential in pheochromocytoma cell lines. <i>Journal of Molecular Endocrinology</i> , 2012, 49, 79-96.	2.5	44
7	Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice. <i>Endocrinology</i> , 2013, 154, 646-655.	2.8	41
8	Metastatic Pheochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 117-128.	1.2	40
9	Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1240-1246.	5.0	35
10	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3295-3307.	3.6	34
11	HIF2 α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	3.1	33
12	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 353-363.	2.3	32
13	Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review. <i>Cancers</i> , 2012, 4, 141-155.	3.7	30
14	Inhibition of Wnt/ β -Catenin Signaling in Neuroendocrine Tumors In Vitro: Antitumoral Effects. <i>Cancers</i> , 2020, 12, 345.	3.7	26
15	The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53 ^{wild type} Neuroendocrine Tumor Cell Line GOT1. <i>Neuroendocrinology</i> , 2018, 106, 1-19.	2.5	25
16	The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, 893-908.	3.1	24
17	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	2.8	24
18	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas—Effect of Different Statins on Mouse Pheochromocytoma Cells. <i>PLoS ONE</i> , 2014, 9, e97712.	2.5	24

#	ARTICLE	IF	CITATIONS
19	Anticancer effects of metformin on neuroendocrine tumor cells in vitro. <i>Hormones</i> , 2014, 13, 498-508.	1.9	23
20	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. <i>Cancers</i> , 2019, 11, 809.	3.7	23
21	The selective PI3K α inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. <i>PLoS ONE</i> , 2017, 12, e0182852.	2.5	23
22	A Method to Perform Western Blots of Microscopic Areas of Histological Sections. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 559-565.	2.5	22
23	Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition. <i>Neuroendocrinology</i> , 2016, 103, 383-401.	2.5	21
24	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1181-e1192.	3.6	19
25	The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. <i>Neuroendocrinology</i> , 2018, 106, 58-73.	2.5	18
26	Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. <i>PLoS ONE</i> , 2015, 10, e0143830.	2.5	16
27	Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. <i>Endocrine-Related Cancer</i> , 2017, 24, R239-R259.	3.1	16
28	Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. <i>Endocrinology</i> , 2014, 155, 2377-2390.	2.8	15
29	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. <i>Endocrinology</i> , 2015, 156, 4094-4104.	2.8	12
30	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	3.1	12
31	The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. <i>PLoS ONE</i> , 2017, 12, e0178375.	2.5	10
32	GSK3 β : A Novel Therapeutic Target for Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2018, 106, 335-351.	2.5	10
33	Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 547-560.	3.1	9
34	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. <i>Hypertension</i> , 2022, 79, 1257-1264.	2.7	8
35	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. <i>Discover Oncology</i> , 2021, 12, 9.	2.1	5
36	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3689-e3698.	3.6	4